Vaxcyte Inc, originally known as SutroVax, is a pioneering biotech firm focused on developing innovative protein vaccines aimed at combating bacterial infectious diseases. At the forefront of its pipeline is VAX-24, a promising vaccine candidate designed to prevent invasive pneumococcal disease. The company is also working on vaccines like VAX-31, VAX-A1, VAX-PG, and VAX-GI, targeting various bacterial pathogens and conditions, including antibiotic resistance and periodontitis. Founded in 2013 and based in San Carlos, California, Vaxcyte is committed to advancing vaccine science to protect global health.
Retail investors who spotted Seth Klarman buying Vaxcyte in May were already two months behind a trade Baupost had quietly begun unwinding. Understanding exactly what got lost in that gap changes how…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
2020 will forever be remembered as the year the coronavirus pandemic broke out. But in the year of the lockdowns, there were also 480 initial public offerings on the U.S. stock market…
